Abstract
Background: Metastatic skin melanoma is—despite multiple international efforts—still a highly aggressive and difficult to treat disease, and coupled with increasing incidence, it’s a significant clinical problem for dermatologists and oncologist alike. If current modern therapies fail the first-line chemotherapeutic for metastatic melanoma remains dacarbazine. Rational combination with novel targeting agents holds potential for improvements on clinical response. The insulin-like growth factor type 1 receptor (IGF-1R) has long been associated with the survival and proliferation of melanoma cells, and β-arrestins have an emerging role in the process.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
